Financial Advisor Update

Three Stocks for Your 'Forever Portfolio'

Stock quotes in this article: VNUS , ELOS , CYNO  

But tattoo removal treatments are painful and expensive. The process consists of lasers basically disintegrating tattoos in anywhere from six to 20 separate treatments. According to the Times story, each treatment is like having rubber bands snapping against your skin, but as the baby boomers age, what was once a picture of Satan on your right shoulder is now just a flabby red grinning face laughing at you. This is a trend we can invest in.

Companies that specialize in tattoo removal aren't focused only on tattoos. Fortunately for us, they tend to specialize in the larger demographic trend of using lasers for aesthetic treatments and cosmetic procedures including wrinkle removal, skin tightening and scar removal. These procedures are growing industrywide at a pace of 30% per year.

The stock in the sector that I believe deserves to be included in a Forever Portfolio is Cynosure(CYNO Quote).

Cynosure also develops lasers for aesthetic treatment -- everything from cellulite removal to varicose vein removal to tattoo removal. You can find some before-and-after shots on the company's Web site.

Again, these are companies that are involved in all aspects of minimally invasive cosmetic treatments, which are riding a huge demographic trend. I plan on covering this space in more depth over the next few weeks. One of the companies I'm particularly interested in has more than $60 million in net cash and 230% year-over-year earnings growth.


Other competitors of Venus Medical Technologies include AngioDynamics(ANGO Quote). and Vascular Solutions(VASC Quote). Competitors of Cynosure include Candela(CLZR Quote), Cutera(CUTR Quote) and Palomar Medical Technologies(PMTI Quote).

  • Loading Comments...
  •  
1 2 3 4
Next >

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin

Please note that due to factors including low market capitalization and/or insufficient public float, we consider VNUS, ELOS and CYNO to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.\

James Altucher is president of Stockpickr LLC, a wholly owned subsidiary of TheStreet.com and part of its network of Web properties, and a managing partner at Formula Capital, an alternative asset management firm that runs a fund of hedge funds. He is also a weekly columnist for the Financial Times and the author of Trade Like a Hedge Fund, Trade Like Warren Buffett and SuperCa$h. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Altucher appreciates your feedback; click here to send him an email.

TheStreet.com has a revenue-sharing relationship with Trader's Library under which it receives a portion of the revenue from purchases by customers directed there from TheStreet.com.

Recent Comments





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,460.69 1,107.81 2,172.29 32.42
Oil *
79.56
UP
115.85
UP
12.18
UP
27.69
UP
0.41
10 Yr
3.24%
SPDR Gold
116.99
+1.12%
+1.11%
+1.29%
+1.28%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services